This article is transferred from: China Medical Tribune
Patient Stories
The young Henan native Mr. H was only 21 years old. He had been to many hospitals for treatment due to “increased stool frequency and unformed stools for more than 3 years”. Crohn’s disease (CD) was diagnosed for the first time. At this time, it is only more than ten days before the new biologic ustekinumab has been officially reduced in price and entered into medical insurance. In order to allow patients to receive better treatment, Professor Feng Baisui, director of the Department of Gastroenterology, has fully communicated with the patient. Efficacy and safety, decision to accept treatment. On January 1, 2022, with the early efforts of Professor Feng Baisui, Mr. H successfully enjoyed the intravenous infusion of ustekinumab 130 mg, becoming the first case of ustekinumab entering medical insurance after the price reduction of ustekinumab in Henan Province. beneficiaries. At present, Mr. H’s symptoms are relieved, and he is expected to receive subcutaneous injection of ustekinumab 90 mg again in 8 weeks.
Patient Stories
of ustekinumab
Medicare reform benefits for IBD patients
The Department of Gastroenterology of the Second Affiliated Hospital of Zhengzhou University was established in 1981, with a history of more than 40 years. It is the earliest key discipline and doctoral degree awarding point in Henan Province. The department established the first IBD center in Henan Province in June 2016. It is composed of a team of professional doctors from general surgery, pathology, imaging, ultrasound, pediatrics, psychology, nutrition and other disciplines. The MDT team is especially good at the diagnosis and treatment of various refractory inflammatory bowel diseases (IBD).
Group photo of IBD team
Trials and hardships
Focus on IBD research for 30 years
As a leader of IBD in Henan Province, Professor Feng Baisui has been focusing on the basic and clinical research of IBD for nearly 30 years and has rich experience in clinical treatment. He has witnessed the glorious development history of IBD in China in just a few decades from the fact that the domestic attention to IBD is not high and the cause of the disease is not well understood. In the interview, Professor Feng Baisui mentioned, “Correct diagnosis is very important for the treatment of IBD. Although China’s IBD diagnosis and treatment have made great progress, even so, there is no gold standard for the diagnosis of IBD in the world, and patients have It is difficult to be cured, but the disease is maintained in remission under comprehensive treatment methods such as drugs to ensure that normal life is not affected. The emergence of the new biological agent ustekinumab has brought light and hope to patients, especially for many clinically refractory patients. It is a very good choice for IBD patients with sex, complex disease and more comorbidities, and it will also receive more attention from clinicians.”
It is reported that ustekinumab is the world’s first biological agent targeting the interleukin pathway, and is a fully human monoclonal antibody produced by transgenic technology. It is the innovation in technology and mechanism that makes it more effective and safer. More importantly, it has a lower proportion of anti-drug antibodies, thereby reducing the risk of patients needing to switch drugs due to secondary loss of response, enabling long-term maintenance of efficacy and long-term benefits for patients.
wholeheartedly for the patient
Build a brand to win word of mouth
After the latest addition to the list of new drugs under the national medical insurance negotiation, the price of ustekinumab 130 mg intravenous infusion dosage form is 2531.24 yuan/bottle, and the price of 90 mg subcutaneous injection dosage form is 7340.6 yuan/piece, a drop of as much as 75%. Reduce the patient’s treatment burden. Professor Feng Baisui was full of praise for the efficiency of the implementation of the new national medical insurance policy in the hospital, “The national medical insurance policy has won the hearts of the people. After learning the news of drug price cuts, we immediately communicated with the Pharmacy Department, Information Department and Medical Insurance Office. Importance and necessity, with the strong support of the hospital leaders, the hospital’s temporary procurement system started quickly, all the way to the green light, and all the preparations were completed before January 1, so that the patients could enjoy the treatment benefits in time on the same day. Afterwards, the drug treatment cost 1012.5 yuan, and the patient was very happy and excited.”
Professor Feng Baisui communicates with IBD patients
It is true that every progress is inseparable from the deep love and passion, responsibility and responsibility, dedication and sweat. Under the leadership of Professor Feng Baisui, the construction of the IBD Center has achieved remarkable results. The first IBD center in Henan Province was established in 2016; the first batch of China IBD quality control regional diagnosis and treatment centers were approved in 2019; in November 2021, it was approved as the Henan Provincial Key Laboratory of Enteric Disease Medicine, taking the lead in establishing standardized fecal bacteria transplantation in the province Laboratory… As the head of the IBD group of the Henan Provincial Digestive Society, Professor Feng Baisui’s long-term strategic vision and dedicated research spirit have created a far-reaching brand influence for the IBD Center and won a good reputation. Patient reputation.
Standardize the whole process of diagnosis and treatment management
IBD Center ushered in a highlight moment
In order to standardize the comprehensive and whole-process management of IBD diseases, Professor Feng Baisui led the construction of the first IBD doctor-patient management platform in Henan Province, and most of the tertiary and secondary hospitals in 17 cities will join this platform. Professor Feng Baisui introduced that the platform also has functions such as patient data management, patient education, primary doctor training and local patient epidemiological data statistics. Primary-level doctors who hope to join the platform can learn more about the standardized diagnosis and treatment of IBD, conduct academic exchanges and guidance, so as to continuously improve their clinical professional skills and ultimately benefit patients.
In order to allow IBD patients to obtain common knowledge of health education in a timely manner, the center has established the WeChat public account “Yu Jian IBD” to help patients fully understand their disease progress and strengthen their awareness of disease self-management. 200 issues of related information and videos have been released so far. At the same time, the center has also established an Internet platform for IBD patients’ health science and medical, nursing, and patient exchanges. It holds public lectures every year, regularly prepares patients’ church and online Q&A interaction, and conducts health science education for patients in an all-round and multi-angle manner by means of medical science. In 2021, the “Yueyue Yu Jian” church activities will be carried out 12 times.
Yujian IBD
>
Church with IBD
“Yueyue Yu Jian” suffers from the church
In addition, under the careful care of Professor Feng Baisui, the annual professional academic event in the field of IBD in Henan – IBD Zhengzhou Forum has formed its own brand characteristics. Every year, the center invites top domestic experts in the field of IBD to come to pass on the treasures, explain the latest progress in diagnosis and treatment of IBD and clinical difficult problems, and the number of participants reaches 200-300. In addition, the center will hold 3-5 provincial tour lectures every year, and it has traveled to nearly ten cities in the province so far, bringing a lot of good news to improve the standardized diagnosis and treatment of IBD doctors at the grassroots level.
>
IBD Zhengzhou Forum
Regarding the next development of the IBD Center, Professor Feng Baisui mentioned, “The diagnosis of IBD requires a comprehensive diagnosis and analysis of clinical, endoscopy, imaging and histopathology. I hope that the next step will be from clinical diagnosis and treatment, scientific research innovation, teaching and learning. Through standardized MDT diagnosis and treatment combined with the optimized combination of existing diagnosis and treatment methods, individualized treatment plans are formulated for patients to maximize the treatment effect. Although we have not yet found a cure for the disease, we hope that through This kind of diagnosis and treatment model can support a world of hope for patients as much as possible.”
Expert introduction
Professor Feng Baisui
Director, Discipline Leader, Chief Physician, Professor, Doctor of Medicine, Doctoral Supervisor, Department of Gastroenterology, Second Affiliated Hospital of Zhengzhou University
Academic: Chief Popular Science Expert of Henan Province, Special Allowance Expert of Henan Provincial Government, Special Government Allowance Expert of the State Council, Director of Zhengzhou University Intestinal Disease Research Center, Director of China IBD Quality Control Regional Center, Director of Henan Provincial Key Laboratory of Enteric Disease Medicine, Henan Province He is the leader of the IBD group of the Provincial Digestive Society, the chairman of the IBD Special Committee of the Henan Provincial Society of Immunology, the chairman of the Digestive Disease Special Committee of the Henan Medical Science Society, the Standing Committee of the IBD Special Committee of the China Medical Education Association, and the IBD Special Committee of the Chinese Association of Integrative Medicine. Vice Chairman of the Association, Vice Chairman of the Capsule Endoscopy and Intestinal Disease Committee of the Chinese Association of Integrative Medicine
Scientific research results: published more than 130 papers, including 40 papers included in SCI. He has presided over more than 20 general projects of the National Natural Science Foundation of China, co-constructed projects of the Ministry of Health and the Ministry of Health, and provincial and ministerial-level scientific research projects.The research results of IBD have won many scientific and technological awards such as the Ministry of Education and the Second Prize of Henan Province Science and Technology Progress Award.